renal cell carcinoma
Metabolism-Based Liquid Biopsy Tool Being Developed by Elypta for Recurrent Renal Cell Cancer
Premium
Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.
Liquid Biopsy Platform Developer Elypta Receives €2.35M in EU Funding
The firm said that it will use the Horizon 2020 Phase II grant to fund a multicenter trial aimed at validating its platform for early detection of recurrent renal cell carcinoma.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.